01 8Entyvio
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 3,085
2018 Revenue in Millions : 2,351
Growth (%) : 31
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 3,823
2019 Revenue in Millions : 3,148
Growth (%) : 21
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 4,267
2020 Revenue in Millions : 3,666
Growth (%) : 25
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 5,199
2021 Revenue in Millions : 4,267
Growth (%) : 22
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 5,280
2022 Revenue in Millions : 5,199
Growth (%) : 15
Main Therapeutic Indication : Anti-Inflammatory
Currency : USD
2016 Revenue in Millions : 1,167
2015 Revenue in Millions : 784
Growth (%) : 49
Main Therapeutic Indication : Anti-inflammatory
Currency : USD
2017 Revenue in Millions : 1,823
2016 Revenue in Millions : 1,245
Growth (%) : 46
Main Therapeutic Indication : Anti-Inflammatory
Currency : USD
2018 Revenue in Millions : 2,276
2017 Revenue in Millions : 1,709
Growth (%) : 33%
